Oxicodona/Naloxona Viatris (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

Oxicodona/Naloxone Viatris is used in the opioid pathway for managing pain conditions requiring strong analgesia.

• Chronic cancer pain: provides sustained relief of moderate to severe nociceptive pain.
• Post‑operative pain: facilitates recovery by controlling acute surgical pain.
• Severe traumatic injury pain: reduces intense pain associated with major trauma.
• Palliative care pain: improves comfort in end‑of‑life settings.
• Chronic non‑cancer pain when other opioids are ineffective: offers an alternative for refractory pain.

• Oxicodone/Naloxone combines an opioid agonist (oxycodone) that activates µ‑mu‑type opioid receptors in the central nervous system to produce analgesia, with naloxone, a peripheral opioid antagonist that limits gastrointestinal opioid effects when the tablet is crushed, thereby reducing the risk of opioid‑induced constipation while preserving central pain control.

Adverse reactions may occur with Oxicodona/Naloxone Viatris and are reported across a spectrum of frequency.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Constipation: reduced bowel motility despite naloxone component.
• Dizziness or light‑headedness: transient vestibular effects.
• Somnolence: sleepiness or reduced alertness.
• Dry mouth: decreased salivation.
• Pruritus: mild skin itching.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing, potentially life‑threatening.
• Severe hypotension: marked drop in blood pressure.
• Opioid use disorder: risk of dependence or addiction.
• Hepatic impairment: elevated liver enzymes or dysfunction.
• Allergic reactions: rash, angioedema, or anaphylaxis.
• adrenal insufficiency: cortisol production abnormalities.

When prescribing Oxicodona/Naloxone, clinicians must consider several safety aspects.

• Assess pain severity and opioid tolerance: ensure appropriate indication and dosage.
• Evaluate respiratory function: monitor for depression, especially in opioid‑naïve patients.
• Review concomitant CNS depressants: avoid additive sedation.
• Monitor for signs of dependence or misuse: implement risk‑mitigation strategies.
• Adjust dose in hepatic or renal impairment: consider reduced clearance.
• Store at ambient temperature: keep in the original packaging, protect from moisture.

Oxicodona/Naloxone may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• CNS‑Centrifugal  ??

-  "); --- ---   ---   "); ---  ---  ---  ---  --- --- --- --- ---\n"""". "); ""  ". ""  ". "" ".